The CEO twice said in past conferences that this un-blinding of clinical data from 51 patients at two sites should give us a rising stock price. Ultimately, imo, the end-game first objective is that PureEP will be a "must have" addition to Afib electrophysiology. The results will lead to a change in SOC protocol. Common sense suggests that third party reimbursements will make Afib EP procedures that do not use Pure EP substantially less profitable. There will be no doubt about integrity of the EP improvement. The count of procedures will be well over 1,000 patients treated by the end of July -- all done by "lead clinicians" in cardiology EP.
As a suggestion, email Andy Ballou (
aballou@biosigtech.com), IR Vice President. Ask him for two positive strategies to pry loose our short-suppressed pps:
1.) With the quarter closed, that Ken release an early, preliminary count of revenues for the quarter in July (... just to stick it to the shorts who harp about BioSig lying about sales). You can pre-empt the short funds and their organized attack narratives set up for the 2nd Qtr release in August: BSGM is the real deal and its just getting started.
2.) Ask the BSGM marketing VP to send the trial abstracts and to inform regarding the potential financial savings implied ... to Medicare managers at the Federal level and at the select states now targeted by BSGM. Longs have tools as well .. "all is fair in love and war." All the best.